Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 1
2013 1
2014 1
2015 4
2016 4
2017 3
2018 3
2019 3
2020 1
2021 2
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Author Reply.
Zimmermann M, Lubinga SJ, Banken R, Rind D, Cramer G, Synnott PG, Chapman RH, Khan S, Carlson J. Zimmermann M, et al. Among authors: lubinga sj. Value Health. 2019 Aug;22(8):972-973. doi: 10.1016/j.jval.2019.03.009. Epub 2019 Jul 22. Value Health. 2019. PMID: 31426939 Free article. No abstract available.
Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.
Willis C, Bauer H, Au TH, Menon J, Unni S, Tran D, Rivers Z, Akerley W, Schabath MB, Badin F, Sekhon A, Patel M, Xia B, Gustafson B, Villano JL, Thomas JM, Lubinga SJ, Cantrell MA, Brixner D, Stenehjem D. Willis C, et al. Among authors: lubinga sj. Oncotarget. 2022 Jan 31;13:257-270. doi: 10.18632/oncotarget.28178. eCollection 2022. Oncotarget. 2022. PMID: 35111281 Free PMC article.
Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.
Willis C, Bauer H, Au TH, Menon J, Unni S, Tran D, Rivers Z, Akerley W, Schabath MB, Badin F, Sekhon A, Patel M, Xia B, Gustafson B, Villano JL, Thomas JM, Lubinga SJ, Cantrell MA, Brixner D, Stenehjem D. Willis C, et al. Among authors: lubinga sj. Oncotarget. 2022 Dec 6;13:1306. doi: 10.18632/oncotarget.28318. Oncotarget. 2022. PMID: 36473137 Free PMC article. No abstract available.
Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Berling M, Chaudhary MA, Yuan Y, Varol N, Dale P, Testa E, Klint J, Lee A, Lubinga SJ, Penrod JR. Berling M, et al. Among authors: lubinga sj. J Med Econ. 2022 Jan-Dec;25(1):703-711. doi: 10.1080/13696998.2022.2077549. J Med Econ. 2022. PMID: 35659172 Free article.
Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M, Sandhu H, Maervoet J, Yuan Y, Chaudhary MA, Varol N, Lee A, Dale P, Jones C, Lubinga SJ, Penrod JR. Polyzoi M, et al. Among authors: lubinga sj. J Med Econ. 2022 Jan-Dec;25(1):660-668. doi: 10.1080/13696998.2022.2048573. J Med Econ. 2022. PMID: 35658806 Free article. Updated.
29 results